Research

ICER meeting on modulator treatments for Cystic Fibrosis.

Serious illness is a leading factor in personal-bankruptcy cases in the United States. There’s a complex web around who is paying for care: Hospitals? Insurance companies? Patients themselves?

On September 9, the USC-Brookings Schaeffer Initiative for Health Policy hosted, in honor of Uwe Reinhardt’s work, the first of three webinars examining whether a larger public role in US healthcare is appropriate.

State laws regarding generic drug and interchangeable biologic substitutions vary widely in the United States, researchers reported.

Drug pricing in America is complex.

A private insurer, UnitedHealthcare, tried to incentivize oncologists to prescribe generic chemotherapies by giving them financial bonuses for doing so.

There’s a widespread perception that transparent pricing would push healthcare prices downward.

The trade-offs get harder in a socialized medical system.

Overall, many U.S. hospitals continue to face significant financial pressure from the pandemic as new infections remain high across much of the country.

Minimum Costs to Manufacture New Treatments for COVID-19.

Characteristics and Price Increases Among Sole-Source, Off-Patent Drugs in the United States, 2008 to 2018

Price difference to foreign countries for patented drugs continues to decrease.

The accepted wisdom in policy circles has been, that while the government can finance basic research, we need to rely on government-granted patent monopolies to pay for the actual development and testing of new drugs.

Setting a payment rate in reference to international prices does not dictate what a manufacturer can charge for a drug – but it does limit how much payers in a state pay.

A new analysis finds three states succeeded in helping their residents save money by capping out-of-pocket costs on pricey specialty drugs.